Problem.

Demonstrating efficacy is challenging with CNS therapeutics.

Only

8%

Phase 1 to FDA approval

Less than

½

as likely as other therapeutic areas

And

2x

as likely to fail in phase 3

CNS diseases are often complex, poorly defined, and difficult to measure. Also, patients are known to exhibit highly differential responses to CNS therapeutics, highlighting the need for patient measurement and stratification.

Solution.

Objective and automated measurement using multimodal AI enhances signal detection.

Screen Shot 2022-06-08 at 2.59.30 PM.png

Increased

power.

Deliberate helps clinical trial sponsors achieve enhanced endpoint reliability, reduced sample size, faster completion, and lower cost.

Screen Shot 2022-06-08 at 2.59.35 PM.png

Comprehensive measurement.

Our platform captures and analyzes signs beyond what a human clinician can perceive, including accurate side effect quantification.

Screen Shot 2022-06-08 at 2.59.43 PM.png

Precision enrollment & enrichment.

With Deliberate, sponsors can screen and verify patients, capture validated baseline measures, and even perform patient enrichment via a companion Dx.

How we do it.

Our multimodal AI platform analyzes biomarker constellations™ to objectively measure disease signs across CNS indications

Distinguished Poster Award

18th Annual Scientific Meeting, 2022

isctm.png

Benefits for sponsors.

Our multimodal AI platform analyzes biomarker constellations™ to objectively measure disease signs across CNS indications

Make your CNS clinical trial
more Deliberate
.

beyond icon-01.png

Measurement beyond human perception

Screen Shot 2022-06-08 at 3.49.19 PM.png

Enhanced signal detection

signal-icon-02.png

Biomarker Constellation analysis and AI-COAs

icons-04.png

Precision enrollment, enrichment, and companion Dx

new sprinkls-01.png

Ready to learn more?